Skip to Main Content

Paper Details

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials.
EClinicalMedicine
9
2022
C-reactive protein, CRP, atherosclerotic cardiovascular disease, glucose, insulin, obesity, overweight, overweight/obesity, participants, people, semaglutide, serum CRP, serum insulin, type 2 diabetes
Author NameAffiliation
John DeanfieldInstitute of Cardiovascular Science, University College London
Mikhail KosiborodSaint Luke's Mid America Heart Institute and University of Missouri-Kansas City School of Medicine
  • 1 - 2

Datasets

Release 1.2